Denali Therapeutics INC Form 4 insider transactions

Denali Therapeutics' CFO and Secretary, Alexander O. Schuth, sold shares to cover tax obligations related to vested restricted stock units.

Denali Therapeutics CEO, Ryan J. Watts, sold shares of company stock to cover tax obligations related to vested restricted stock units.

Denali Therapeutics director Steve E. Krognes sold 3,339 shares of common stock at $20.81 per share to cover tax obligations related to vested restricted stock units.

Denali Therapeutics CEO Ryan Watts acquired 54,180 shares of common stock and 162,540 stock options, while also holding 2,202,604 shares indirectly through a family trust.

Alexander Schuth, COFO and Secretary of Denali Therapeutics, reported the acquisition of restricted stock units and stock options, as well as adjustments to his holdings.

Denali Therapeutics' Chief Medical Officer, Carole Ho, reported the acquisition of stock and stock options, along with adjustments to existing holdings, on January 3, 2025.

Director Steve Krognes of Denali Therapeutics reports the sale of 30,000 shares of common stock on December 31, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Vicki L Sato reported selling 3,080 shares of Denali Therapeutics Inc. on January 2, 2025, at a weighted average price of $20.91.

Alexander O. Schuth, COFO and Secretary of Denali Therapeutics, exercised stock options and acquired 6,708 shares of common stock on December 27, 2024.

Denali Therapeutics' Chief Medical Officer, Carole Ho, exercised stock options and acquired shares, increasing her holdings in the company.

Denali Therapeutics' Chief Financial Officer and Secretary, Alexander O. Schuth, exercised stock options and acquired 20,516 shares of common stock on November 22, 2024.

Denali Therapeutics director David P. Schenkein exercised stock options and sold shares on November 11, 2024, according to a recent SEC filing.

Alexander O. Schuth, CFO of Denali Therapeutics, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Director Vicki L. Sato of Denali Therapeutics Inc. reported selling 1,020 shares of common stock at $30 per share on November 7, 2024, under a pre-arranged 10b5-1 trading plan.

Director Vicki L. Sato of Denali Therapeutics Inc. reports selling 3,080 shares of common stock at an average price of $27.07.

Ryan Watts, CEO of Denali Therapeutics, exercised stock options and sold 40,000 shares of common stock at an average price of $27.69, while also holding over 2 million shares indirectly through a family trust.

Director Steve Krognes of Denali Therapeutics sold 30,000 shares of common stock on September 30, 2024, at a weighted average price of $29.03 per share.

Director Vicki L Sato of Denali Therapeutics Inc. sold 1,020 shares of common stock at $30 per share on September 13, 2024, according to a Form 4 filing.

Director Vicki L. Sato reported selling shares of Denali Therapeutics Inc. under a pre-arranged Rule 10b5-1 trading plan.

Denali Therapeutics CEO Ryan J. Watts sold 2,260 shares of common stock on August 20, 2024, to satisfy tax obligations related to the settlement of previously vested restricted stock units.

Director Steve E. Krognes sold 1,727 shares of Denali Therapeutics Inc. to satisfy tax obligations related to vested restricted stock units.

Alexander Schuth, COFO and Secretary of Denali Therapeutics, sold shares of common stock to cover tax obligations related to vested restricted stock units, according to a Form 4 filing.

Chief Medical Officer of Denali Therapeutics, Carole Ho, sold shares of DNLI stock on August 20 and 21, 2024, to cover tax obligations and under a pre-arranged 10b5-1 trading plan.

Alexander O. Schuth, COFO and Secretary of Denali Therapeutics Inc., sold 2,272 shares of common stock on August 13, 2024, to satisfy tax obligations related to vested restricted stock units.

Carole Ho, Chief Medical Officer of Denali Therapeutics, sold 2,337 shares of common stock on August 13, 2024, to satisfy tax obligations related to vested restricted stock units.

Director Steve Krognes of Denali Therapeutics reports the sale of common stock, including transactions made under a Rule 10b5-1 trading plan.

Director Vicki L. Sato reported selling shares of Denali Therapeutics Inc. on July 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Jennifer E. Cook sold 1,458 shares of Denali Therapeutics Inc. (DNLI) on June 6, 2024, at a price of $21.73 per share, according to a Form 4 filing with the SEC.

Director Steve Krognes reports acquisition of Denali Therapeutics stock and options, including restricted stock units and options vesting within one year.

Director Nancy Thornberry reports acquisition of stock and options in Denali Therapeutics on May 31, 2024.